瑞芬太尼与右美托咪定用于心脏术后无创通气不耐受患者:多中心随机对照试验
本研究为多中心、前瞻性、单盲随机对照试验,纳入179例心脏术后中重度无创通气不耐受的成人患者,随机分为瑞芬太尼组(89例)和右美托咪定组(90例),比较两种镇静药物对无创通气不耐受的缓解率。主要结局显示,除15分钟时间点外(42% vs 20%,p=0.002),大多数时间点缓解率无显著差异;但采用广义估计方程考虑时间因素后,瑞芬太尼显著优于右美托咪定(OR 3.31,95%CI 1.35-8.12,p=0.009)。右美托咪定组9例出现不良事件(3例心动过缓、6例严重低血压),瑞芬太尼组未报告。两组在无创通气失败、气管切开、ICU住院时间和院内死亡率方面无显著差异。
要点
- 心脏术后中重度无创通气不耐受患者,瑞芬太尼组15分钟缓解率为42%,右美托咪定组为20%(p=0.002)。
- 考虑时间因素后,瑞芬太尼缓解无创通气不耐受的OR为3.31(95%CI 1.35-8.12,p=0.009),显著优于右美托咪定。
- 右美托咪定组9例出现不良事件(3例心动过缓、6例严重低血压),瑞芬太尼组未报告不良事件。
- 两组无创通气失败率(5.6% vs 7.8%,p=0.564)、气管切开率(1.12% vs 0%,p=0.313)、ICU住院时间(7.7天 vs 7.0天,p=0.219)和院内死亡率(1.12% vs 2.22%,p=0.567)无显著差异。
适用人群与场景
- 成人心脏术后患者,存在中重度无创通气不耐受,纳入本多中心、前瞻性、单盲随机对照试验。
诊断标准与关键阈值
- 采用四点无创通气不耐受评分评估不耐受状态,基线评分瑞芬太尼组为3(IQR 3-3),右美托咪定组为3(IQR 3-4),p=0.180。
处置流程与药物剂量
- 瑞芬太尼组:使用瑞芬太尼镇静;右美托咪定组:使用右美托咪定镇静;具体剂量、给药途径、频次和疗程原文未给出。
红旗征与不能漏的情况
- 右美托咪定组报告3例心动过缓、6例严重低血压。
研究设计与关键结果
- 多中心、前瞻性、单盲随机对照试验,纳入179例心脏术后中重度无创通气不耐受成人患者,瑞芬太尼组89例,右美托咪定组90例。
- 主要结局:缓解率(从初始不耐受状态缓解的患者比例)在大多数时间点无显著差异,仅15分钟时间点瑞芬太尼组42% vs 右美托咪定组20%(p=0.002)。
- 广义估计方程考虑时间因素后,瑞芬太尼优于右美托咪定(OR=3.31,95%CI 1.35-8.12,p=0.009)。
- 不良事件:瑞芬太尼组未报告,右美托咪定组9例(3例心动过缓,6例严重低血压)。
- 次要结局:无创通气失败率5.6% vs 7.8%(p=0.564);气管切开率1.12% vs 0%(p=0.313);ICU住院时间7.7天(IQR 5.8-12)vs 7.0天(IQR 5-10.6)(p=0.219);院内死亡率1.12% vs 2.22%(p=0.567)。
证据类型、等级与局限
- 证据类型:多中心、前瞻性、单盲随机对照试验。
- 局限:原文未报告局限性。
对床旁实践的改变
- 对于心脏术后中重度无创通气不耐受的成人患者,作者认为考虑时间因素后瑞芬太尼在缓解不耐受方面显著优于右美托咪定。
- 右美托咪定组出现心动过缓和严重低血压不良事件,瑞芬太尼组未报告。
指南或共识出处
- 临床试验注册号:ClinicalTrials.gov NCT04734418,注册日期2021年1月22日。
提炼说明
- 本条依据论文摘要整理;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: The optimal sedative regime for noninvasive ventilation (NIV) intolerance remains uncertain. The present study aimed to assess the efficacy and safety of remifentanil (REM) compared to dexmedetomidine (DEX) in cardiac surgery patients with moderate-to-severe intolerance to NIV.
METHODS: In this multicenter, prospective, single-blind, randomized controlled study, adult cardiac surgery patients with moderate-to-severe intolerance to NIV were enrolled and randomly assigned to be treated with either REM or DEX for sedation. The status of NIV intolerance was evaluated using a four-point NIV intolerance score at different timepoints within a 72-h period. The primary outcome was the mitigation rate of NIV intolerance following sedation.
RESULTS: A total of 179 patients were enrolled, with 89 assigned to the REM group and 90 to the DEX group. Baseline characteristics were comparable between the two groups, including NIV intolerance score [3, interquartile range (IQR) 3-3 vs. 3, IQR 3-4, p = 0.180]. The chi-squared test showed that mitigation rate, defined as the proportion of patients who were relieved from their initial intolerance status, was not significant at most timepoints, except for the 15-min timepoint (42% vs. 20%, p = 0.002). However, after considering the time factor, generalized estimating equations showed that the difference was statistically significant, and REM outperformed DEX (odds ratio = 3.31, 95% confidence interval: 1.35-8.12, p = 0.009). Adverse effects, which were not reported in the REM group, were encountered by nine patients in the DEX group, with three instances of bradycardia and six cases of severe hypotension. Secondary outcomes, including NIV failure (5.6% vs. 7.8%, p = 0.564), tracheostomy (1.12% vs. 0%, p = 0.313), ICU LOS (7.7 days, IQR 5.8-12 days vs. 7.0 days, IQR 5-10.6 days, p = 0.219), and in-hospital mortality (1.12% vs. 2.22%, p = 0.567), demonstrated comparability between the two groups.
CONCLUSIONS: In summary, our study demonstrated no significant difference between REM and DEX in the percentage of patients who achieved mitigation among cardiac surgery patients with moderate-to-severe NIV intolerance. However, after considering the time factor, REM was significantly superior to DEX. Trial registration ClinicalTrials.gov (NCT04734418), registered on January 22, 2021. URL of the trial registry record: https://register.
CLINICALTRIALS: gov/prs/app/action/SelectProtocol?sid=S000AM4S&selectaction=Edit&uid=U00038YX&ts=3&cx=eqn1z0 .
参考来源
- Hao GW, Wu JQ, Yu SJ, et al. Remifentanil vs. dexmedetomidine for cardiac surgery patients with noninvasive ventilation intolerance: a multicenter randomized controlled trial. J Intensive Care. 2024. PMID: 39294818. doi:10.1186/s40560-024-00750-2
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。